In the REPLACE-2 trial, bivalirudin monotherapy was shown to be as effective as UFH plus GP IIb/IIIa inhibitors and safer during PCI in patients with stable and unstable coronary syndromes.

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic ... acute coronary syndrome, but the ...

Acute coronary syndromes are sudden episodes of reduced or no blood flow and therefore oxygen delivery to part of the heart, usually as a result of narrowing or blockage of an artery.

Study Objectives: The clinical manifestations of acute coronary syndromes (ACSs) vary, and patients present frequently with symptoms other than chest pain. In this analysis, a large contemporary ...